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ABSTRACT
‘miR2Disease’, a manually curated database, aims at
providing a comprehensive resource of microRNA
deregulation in various human diseases. The current
version of miR2Disease documents 1939 curated
relationships between 299 human microRNAs and
94 human diseases by reviewing more than 600
published papers. Around one-seventh of the
microRNA–disease relationships represent the
pathogenic roles of deregulated microRNA in
human disease. Each entry in the miR2Disease
contains detailed information on a microRNA–
disease relationship, including a microRNA ID,
the disease name, a brief description of the
microRNA–disease relationship, an expression
pattern of the microRNA, the detection method
for microRNA expression, experimentally verified
target gene(s) of the microRNA and a literature refer-
ence. miR2Disease provides a user-friendly interface
for a convenient retrieval of each entry by microRNA
ID, disease name, or target gene. In addition,
miR2Disease offers a submission page that allows
researchers to submit established microRNA–
disease relationships that are not documented.
Onceapprovedbythesubmissionreviewcommittee,
the submitted records will be included in the data-
base. miR2Disease is freely available at http://
www.miR2Disease.org.
INTRODUCTION
MicroRNAs are a class of endogenous single-stranded
small noncoding RNAs that negatively regulate gene
expression (1). MicroRNAs control mRNA degradation
and/or translation inhibition through binding to comple-
mentary sites in the 30-untranslated regions of target
genes (2). In the past decade, hundreds of microRNAs
have been identiﬁed in mammalian cells (3,4). Evidence
suggests that microRNAs play critical roles in multiple
biological processes, including cell cycle control, cell
growth and diﬀerentiation, apoptosis, embryo develop-
ment and so on (5–8).
In recent years, dozens of microRNA-related data-
base systems have been developed. miRBase (9),
miRGator (10) and miRGen (11) aim at providing
complete repositories for microRNA annotation and
nomenclature. TarBase (12), microRNAMap 2.0 (13)
and microRNA.org (14) collect experimentally validated
and/or computationally predicted microRNA–target rela-
tionships; microRNA.org also provides a collection of
microRNA expression proﬁles in diﬀerent tissues. Such
database systems oﬀer great resources in investigating
the function of microRNA in gene regulation. In addition,
several computational algorithms and web-based pro-
grams have been developed to computationally predict
target genes/sites of microRNAs, such as TargetScan
(15), PicTar (16), RNAhybrid (17) and PITA (18).
Accumulating evidence indicates that microRNAs play
crucial roles in human disease development, progression,
prognosis, diagnosis and evaluation of treatment response
(19–24). Genome-wide association studies demonstrated
that many human microRNA genes locate at genomic
regions linked to cancer (25,26). Moreover, a recent
study found that the absolute expression levels of many
microRNAs were reduced signiﬁcantly in tumors (27).
The same study also revealed that using the expression
levels of 217 microRNAs were more eﬀective in cancer
classiﬁcation than mRNA microarrays containing more
than 16000 protein-coding genes (27). All these evidences
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tion of microRNA in disease development.
In addition to these genome-wide studies, correlations
between single microRNA deregulation and occurrences
of human disease have been reported. Cimmino et al. (28)
demonstrated that both miR-15a and miR-16-1 negatively
regulate BCL2at a post-transcriptional level, which
induces apoptosis in a leukemic cell line model. Yang
et al. (29) found that miR-1 overexpression slowed cardiac
conduction and depolarized the cytoplasmic membrane by
post-transcriptionally repressing KCNJ2 and GJA1,
which accounted at least in part for its arrhythmogenic
potential. Hitherto, over 100 review papers have been
published in summarizing the relationship between
microRNA deregulation and dozens of diseases (30–36).
Despite these developments, detailed information on
microRNA–disease relationships are scattered in litera-
tures and there is no online repository for these
microRNA–disease relationships. Therefore, we develop
a manually curated database entitled ‘miR2Disease’
(http://www.miR2Disease.org), which provides a compre-
hensive resource of microRNA deregulation in various
human diseases.
DATA COLLECTION AND DATABASE CONTENT
Initial entries describing the relationships between
microRNA deregulation and occurrences of human dis-
ease are collected manually. We searched the PubMed
database (37) with a list of keywords, such as
‘microRNA disease’, ‘miRNA disease’, ‘microRNA
cancer’, ‘miRNA cancer’, etc. In the current release of
miR2Disease, more than 600 literatures were reviewed,
and 1939 curated relationships between 299 human
microRNAs and 94 human diseases were documented.
In the miR2Disease system, the disease terminologies
were organized based upon a controlled medical vocabu-
lary (Disease Ontology: http://diseaseontology.source
forge.net/), which utilizes the Uniﬁed Medical Language
System (UMLS) as source vocabulary (38). Such organi-
zation provides substantial advantage in terms of search
and analysis. Each entry in the database contains detailed
information on a microRNA–disease relationship, includ-
ing a microRNA ID, the disease name, a brief description
of the microRNA–disease relationship, an expression pat-
tern of microRNA (upregulated or downregulated) in
the disease state, the detection method used to derive
microRNA expression pattern (microarray, northern
blot, qRT-PCR, etc.), the experimentally validated target
gene(s) extracted from the corresponding references and
directly derived from TarBase and a literature reference.
miR2Disease provides a user-friendly interface for an
easy query of each entry by microRNA ID, disease
name or experimentally validated target genes. In addi-
tion, convenient links are provided to other microRNA
databases, including microRNA sequence and annota-
tion in miRBase, experimentally validated microRNA
target genes in TarBase and computationally predicted
microRNA target genes in TargetScan, miRanda and
PicTar. A hyper link to the literature reference in the
NCBI PubMed database (37) together with an oﬃcial
PubMed ID and complete citation are also provided.
In miR2Disease, around one-seventh of the microRNA–
disease relationships represent the pathogenic roles of
deregulated microRNA in human disease.
USER INTERFACE
Searchpage
miR2Disease provides a search engine to query detailed
information on each microRNA–disease relationship
documented in the database. Users can query the database
through microRNA ID, disease name or target genes.
miR2Disease oﬀers a fuzzy search function. Combining
with controlled disease vocabulary (disease ontology),
fuzzy search functionality allows users to retrieve mean-
ingful microRNA–disease relationship information with-
out knowing the exact disease name documented in the
database. Once certain disease name is received as a
query term, the system ﬁrst searches all the disease ter-
minologies that contain the query words. The matching
disease terminology will be listed in the context of a dis-
ease tree, which contains its ancestor nodes as well as all of
its subcategories. In the matching disease tree, the cate-
gories that contain query terminologies are highlighted as
bold, and a hyperlink is created for every category that
contains documented microRNA–disease relationships.
Through these hyperlinks, users can retrieve all the
microRNA entries that are related to the selected disease
terminology. In the search results page, clicking the
‘more...’ link at the end of the entry will lead to detail
information of this relationship (Figure 1).
Similar to search by disease terminology, the nomencla-
tures of microRNAs could be complicated and confusing.
It is not unusual that the original publication did not
provide enough information on the exact microRNA in
a large microRNA family. For instance, some publica-
tions simply report let-7 is related to adenoma, while
others conclude that the expression level of let-7a-3 is
downregulated in breast cancer. Therefore, through the
fuzzy search function, miR2Diesease allows queries of
microRNAs without knowing their exact identiﬁcation
numbers. Under the circumstances that one microRNA
query results in multiple IDs, one can further select the
microRNAs of the greatest interests. Similarly, Figure 1
provides a snapshot of the query workﬂow of ‘search by
miRNA ID’.
In the miR2Disease system, the concept of target genes
can be classiﬁed into three categories: the target genes
reported in the original reference, the target genes docu-
mented in the TarBase system (experimentally validated
targets) and the predicted targets from computational
tools (Miranda, TargetScan or PicTar). The ‘search’ by
‘target genes’ functionality allows users to search
microRNA–disease relationships from the target genes
of the ﬁrst two types (reported targets and experimentally
validated targets). Searching through the computationally
predicted targets will be included in the future release.
The causal relationship between disease and microRNA
is documented and listed in both the searching result page
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the system also allows users to ﬁlter the search results by
only selecting causal relationships.
Submitpage
miR2Disease provides a submission page that allows other
researchers to submit important microRNA–disease rela-
tionships that are not documented. Once approved by the
submission review committee, the submitted record will be
included in the database, and made available to the public
in the coming release. miR2Disease will be updated
monthly.
DISCUSSION
Emerging evidence suggests that speciﬁc temporal and spa-
tial microRNA expression is required for normal cellular
development and diﬀerentiation, whereas many human
diseases are associated with aberrant microRNA expres-
sion patterns. In order to provide a central resource for the
biologists who study the relationship between microRNA
and human disease, we develop miR2Disease, a database
system aiming at providing a comprehensive resource of
microRNA deregulation in various human diseases.
miR2Disease not only oﬀers an easy-to-use web interface
to query the detailed information on microRNA–disease
relationships documented in the database, but it also pro-
vides a submission page that allows other researchers to
contribute to the data contents.
Figure 2A demonstrates the histogram of the number of
diseases associated with the microRNAs archived in the
database. Eighty-seven microRNAs (29.1%) are deregu-
lated in only one disease; while 177 microRNAs (59.2%)
demonstrate deregulation in no more than three diseases.
The most prevalent microRNA appeared in the database
is hsa-miR-21, which is deregulated in 59 documented
diseases (over half of all the disease types). Five additional
microRNAs are deregulated in over 25 types of diseases;
they are: hsa-miR-155, hsa-miR-221, hsa-let-7a, hsa-miR-
223 and hsa-miR-222, which are related to 45, 37, 28,
25 and 25 diseases, respectively. The histogram of the
number of deregulated microRNAs associated with indi-
vidual disease is shown in Figure 2B. No more than three
microRNA deregulations were documented for 37 diseases
(39.4%), 21 of which contain only one record. On the
contrary, 13 diseases are related to more than 50 deregu-
lated microRNAs. Hepatocellular carcinoma, prostate
Figure 1. A schematic workﬂow of miR2Disease.
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129, 98 and 87 deregulated microRNAs associated. One
should notice that these numbers are highly dependent on
the experimental approaches being used in the original
publication. For instance, investigations using microarray
technology usually observe more deregulated microRNAs
than other low-throughput studies.
It remains to be seen whether the deregulation of
microRNAs is a cause or consequence of the disease
state. Around 1/7 of the microRNA–disease relationships
in miR2Disease indicate the pathogenic role of microRNA
deregulation in various diseases, including cancer, meta-
bolic disease and cardiovascular disease. For instance, Ma
et al. (39) reported that highly expressed miR-10b initiates
tumor invasion and metastasis in breast cancer through
translational inhibition of HOXD10, and eventually
increases expression of RHOC, a pro-metastatic gene.
Huang et al. (40) found that signiﬁcant upregulation of
miR-373 and miR-520c stimulates breast cancer cell
migration and invasion by the suppression of CD44.
Figure 2. Distribution of diseases and deregulated microRNAs documented in miR2Disease database. (A) Histogram of the number of diseases
associated with individual microRNA. (B) Histogram of the number of deregulated microRNAs associated with individual disease.
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activated protein kinase kinase kinase 8 (MAP3K8) is a
target of miR-370, whose reduced expression elevates the
MAP3K8 level and therefore contributes to tumor growth
in cholangiocarcinoma. It has been reported that miR-375
controls insulin secretion by regulating the expression of
myotrophin. Upregulation of miR-375 led to an enhanced
inhibition of insulin release (42). It is also demonstrated
that downregulation of miR-1 and miR-133 contributes to
re-expression of HCN2/HCN4 and the electrical remodel-
ing process in hypertrophic hearts (43).
Information in the miR2Disease can be used to describe
the relationship among multiple diseases. To this end, we
create a bipartite network that describes the causal rela-
tionship between 85 microRNAs and 32 cancer-related
diseases (Figure 3). Within this network, lung carcinoma,
breast cancer and ovarian cancer demonstrate the highest
connectivity by aﬃliating with 25, 23 and 18 causal
microRNAs, respectively. For microRNAs, hsa-let-7a
deregulation is the causal eﬀect for nine types of cancers,
while hsa-miR-21, hsa-miR-124a, hsa-let-7c, hsa-miR-145,
hsa-miR-16 and hsa-miR-221, each associate with ﬁve
types of cancers or more (solid circles in the network).
Using miR2Disease database, one can create this type of
bipartite network by searching for the diseases or
microRNAs of interest.
miR2Disease documented several potential mechanisms
that cause the microRNA deregulation in various human
diseases. First, microRNAs are located in the disease-
causing genomic loci, including minimal regions of loss
of heterozygosity, minimal amplicon, or breakpoint clus-
ter regions (19,25). For instance, miR-15 and miR-16 are
located in chromosome 13q14, a region that is deleted in
more than half of B-cell chronic lymphocytic leukemia
(CLL)s (B-CLL); consequently, both genes are deleted
or downregulated in the majority (68%) of CLL cases
(44). In contrast, the miR-17-92 polycistron is located in
a genomic region that is ampliﬁed in human B-cell lym-
phomas, and therefore are overexpressed (45). Second,
microRNA deregulation is caused by abnormal epigenetic
patterns, including abnormal DNA methylation and
histone-modiﬁcation patterns (46). For instance, in
normal conditions, the putative promoter region of let-
7a-3 gene is heavily methylated in normal human tissues,
Figure 3. A bipartite network demonstrating the causal relationship between deregulated microRNAs and variety of cancers. Circles and rectangles
correspond to microRNAs and diseases, respectively. An edge is placed between a microRNA and a disease if the microRNA deregulation plays
causative role in pathogenesis of the disease. Solid circles indicate master microRNAs that potentially cause no less than ﬁve types of cancers.
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moter demethylation induced reactivation of the let-7a-3
with an oncogenic function and increased proliferation in
lung cancer cell lines (47). In addition, aberrant hyper-
methylation leads to miR-9-1 inactivation in human
breast cancer (48). Third, microRNA deregulation may
be caused by abnormalities of the enzymes that are
involved in microRNA biogenesis. For example, Otsuka
et al. (49) unambiguously showed that miR-24 and miR-
93 could target viral large protein (L protein) and phos-
phoprotein (P protein) genes. In Dicer1-deﬁcient cells, a
lack of host miR-24 and miR-93 was responsible for
increased VSV replication. In the miR2Disease system,
such information is documented in the ‘analysis’ session
(a link through the home page).
In addition to the mechanisms described above,
miR2Disease also contains entries where disease-causing
genetic variations aﬀect cellular functions through the dis-
ruption of microRNA target selection. For instance,
loss-of-interaction variations in let-7:Hmga2 (50), miR-
148a:HLA-G (51) and miR-433:FGF20 (52), are involved
in myoma, asthma and Parkinson’s disease, respectively.
Chen et al. (53) elucidated that CCND1 mRNA is nor-
mally under the regulation of miR-16-1, and that truncated
CCND1 mRNA escapes this regulation through deletion
of the microRNA-binding sites in mantle cell lymphoma.
In summary, loss-of-interaction variations in microRNA
genes or the binding site(s) of microRNA represent a newly
described pathogenic mechanism of disease.
Overall, miR2Disease provides a comprehensive
resource of microRNA deregulation in human disease.
We believe that miR2Disease will be of particular interest
to the life science community and facilitates the biologists
to unravel the role of microRNA in the pathogenesis of
human disease.
FUTURE DEVELOPMENT
As stated in the ‘data collection and database content’
session, the microRNA–disease relationships documented
in the current release were collected through searching
the PubMed database with a list of keywords, such
as ‘microRNA disease’, ‘miRNA disease’, ‘microRNA
cancer’, ‘miRNA cancer’, etc. Although we collected
 2000 relationships from over 600 literatures, such mecha-
nism suﬀers from the lack of comprehensiveness and
systematicness. We plan to adopt two strategies to improve
our data collection. First, we will use text-mining tools
to help us prescreen PubMed abstracts that potentially
describe the microRNA–disease relationships. Second,
we will speciﬁcally target MeSH (Medical Subject
Headings) vocabularies that are created and maintained
at the National Library of Medicine. These strategies will
no doubt increase the data comprehensiveness, and will
impact the database records in the releases to come.
DISCLAIMER
Not all relationships of microRNA in disease are equally
valid. Some studies demonstrated more creditable
microRNA–disease relationships than others.
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